Bibliographie

1. Berenson GS, Srinivasan ST, Bao W et al, for the Bogalusa Heart Study. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med 1998; 338: 1650-1656.

2. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011;128 Suppl.5:S213-56.

3. Daniels SR, Greer FR and the committee on nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics 2008; 122: 198-208.

4. National Cholesterol Education Program. Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992; 89: 525-84.

5. Girardet JP, Luc G, Rieu D et al. Prise en charge des hypercholestérolémies de l’enfant : recommandations du Comité de nutrition de la Société Française de Pédiatrie et de la Nouvelle Société Française d’Athérosclérose. Arch Pédiatr 2011;18 :217-29.

6. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Eds. The metabolic basis of inherited disease. New York: Mc Graw-Hill, 2001; 2863-2913.

7. Goldberg AC, Hopkins PN, Toth PP et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients. Clinical guidance from the National Lipid Association Expert Panel on Familial hypercholesterolemia. J Clin Lipidol 2011; 5 (suppl):S1-S8.

8. McCrindle BW, Urbina EM, Dennison BA et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007; 115: 1948-67.

9. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004; 160: 407-20.

10. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Athero- sclerosis 2004; 173: 55-68.

11. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolemia: implications for clinical management. Atherosclerosis 1999;142: 105-12.

12. Lebars MA, Rieu D, Girardet JP. Traitement diététique de l’hypercholestérolémie de l’enfant. Arch Pediatr 2010; 17:1126-32.

13. Benlian P, Turquet A, Carrat F et al. Diagnosis scoring for clinical identification of children with heterozygous familial hypercholesterolemia. J Pediat Gastroenterol Nutr 2009 ; 48: 456-63.

14. Vuorio A, Kuoppala J, Kovanen PT et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2010 Jul 7 CD006401.

15. Wiegman A, Hutten BA, De Groot E et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004; 292: 331-7.

16. Winterfeld U, Allignol A, Panchaud A et al. Pregnancy outcome following maternal exposure

to statins: a multicentre prospective study. BJOG. 2013;120:463-71.

17. Wald DS, Bestwick JP, Wald NJ. Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. B Med J 2007; 335: 599.